Fergus McTaggart

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.

Fergus McTaggart, Linda K. Buckett, Robert G. Davidson et al. · The American Journal of Cardiology · 2001 · 412 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +12

Inhibitors of 3-Hydroxy-3-Methylglutaryl–CoA Reductase Reduce Receptor-Mediated Endocytosis in Opossum Kidney Cells

James E. Sidaway, Robert G. Davidson, Fergus McTaggart et al. · Journal of the American Society of Nephrology · 2004 · 156 citations

Albumin Uptake, Cytoskeleton, Nephrology +21

Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia

Muriel Caslake, Grace Stewart, Stephen Day et al. · Atherosclerosis · 2003 · 89 citations

Metabolic Syndrome, Atherogenic Lipoprotein Subfractions, -Independent Actions +13

Comparison of the Effects of High Doses of Rosuvastatin Versus Atorvastatin on the Subpopulations of High-Density Lipoproteins

Bela F. Asztalos, Florence Le Maulf, Gerald E. Dallal et al. · The American Journal of Cardiology · 2007 · 84 citations

Thrombosis, Cardiovascular Disease, Medicine +9

Effect of Short-Term Rosuvastatin Treatment on Estimated Glomerular Filtration Rate

Donald G. Vidt, Susan S. Harris, Fergus McTaggart et al. · The American Journal of Cardiology · 2006 · 74 citations

Hemodialysis, Urology, Renal Function +7